18. Which of the following is true about glycoprotein IIb/IIIa inhibitors?

A. Are recommended for use prior to percutaneous coronary intervention in high risk ST elevation myocardial infarction patients

B. Are recommended for use at the time of percutaneous coronary intervention in patients with ST elevation myocardial infarction

C. Glycoprotein IIb/IIIa inhibitors should not be used simultaneously with bivalirudin

D. All of the above are true


These drugs include abciximab, eptifibatide, and tirofiban. They very strongly inhibit platelet function by blocking the binding of fibrinogen to the activated glycoprotein IIb/IIIa receptor complex. Any of these agents may be used in addition to aspirin, a thienopyridine and anticoagulation (except with bivalirudin) at the time of PCI in high risk patients with STEMI. Using glycoprotein IIb/IIIa inhibitors prior to PCI does not have strong data to support its use at the present time.